Login / Signup

Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes.

Patrick R LawlerHongyan LiuClaudia FrankfurterLeif Erik LovblomYuliya LytvynDylan BurgerKevin D BurnsDavor BrincDavid Z I Cherney
Published in: Diabetes care (2021)
Keyphrases
  • type diabetes
  • glycemic control
  • cardiovascular disease
  • insulin resistance